Recro to Report Financial Results for First Quarter 2021 on May 6

Rhea-AI Summary

Recro Pharma (REPH) will release its Q1 2021 financial results on May 6, 2021, after market close. A conference call and audio webcast will follow at 4:30 p.m. ET to discuss the results and operational updates. As a contract development and manufacturing organization, Recro specializes in oral solid dose drug products, offering services from feasibility to commercial manufacturing, with a focus on complex formulations. The company operates a 120,000 square foot facility in Gainesville, Georgia, and supports clients in pharmaceutical development.

Positive

• Scheduled release of Q1 2021 financial results, indicating transparency.
• Expertise in complex formulation manufacturing may attract more clients.

Negative

• None.

Conference Call and Webcast Scheduled for Thursday, May 6 at 4:30 p.m. Eastern Time

MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that the company will release financial results for the first quarter 2021 after the market close on Thursday, May 6, 2021. Recro’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, May 6, 2021 to discuss the financial results and recent operational highlights.

To access the live conference call please dial (844) 243-4691 from the U.S. or (225) 283-0379 from outside the U.S. at least ten minutes prior to the start time and reference conference ID 4898666. Those interested in listening to the conference call live via webcast may do so by visiting the “Events” page in the Investor section of the Company’s website, www.recrocdmo.com. In addition, an archived webcast will be available on the Company’s website approximately two hours after the event and will be available for 30 days.

About Recro
Recro (NASD: REPH) is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.

In addition to our experience in handling DEA controlled substances and developing and manufacturing modified release oral solid dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 120,000 square feet, in Gainesville, Georgia.

For more information about Recro’s CDMO solutions, visit recrocdmo.com.

FAQ

When will Recro Pharma release its Q1 2021 financial results?

Recro Pharma will release its Q1 2021 financial results on May 6, 2021.

What time is Recro Pharma's conference call on May 6, 2021?

The conference call is scheduled for 4:30 p.m. ET on May 6, 2021.

How can I access the Recro Pharma conference call?

You can access the Recro Pharma conference call by dialing (844) 243-4691 from the U.S. or (225) 283-0379 from outside the U.S.

What services does Recro Pharma provide?

Recro Pharma provides contract development and manufacturing services, focusing on oral solid dosage forms, regulatory support, and packaging.

Where is Recro Pharma's facility located?

Recro Pharma operates a 120,000 square foot facility in Gainesville, Georgia.